FADROZOLE HYDROCHLORIDE Property

Melting point:

231-233℃

storage temp. 

room temp

solubility 

DMSO: >20mg/mL

form 

powder

color 

Pale Beige to Pale Yellow

Stability:

Hygroscopic

Safety

Hazard Codes 

Xn

Risk Statements 

63-22

Safety Statements 

36/37

RIDADR 

UN 2811 6.1 / PGIII

WGK Germany 

2

RTECS 

DI4952500

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H301Toxic if swalloed

H361Suspected of damaging fertility or the unborn child

Precautionary statements

P202Do not handle until all safety precautions have been read and understood.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P301+P310IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.

P405Store locked up.

FADROZOLE HYDROCHLORIDE Chemical Properties,Usage,Production

Description

Fadrozole hydrochloride is a non-steroidal imidazole derivative launched for the treatment of post-menopausal breast cancer. Fadrozole is a potent and specific aromatase inhibitor with neither androgenic nor estrogenic activities due to its structural novelty. Fadrozole exerts its action by coordinating with the iron of the porphyrin nucleus, presumably through the imidazole moiety. This strong binding competes with the binding of molecular oxygen to iron and reversibly inactivates the enzyme. An excellent clinical response rate has been reported for fadrozole with no significant side effects.

Originator

Ciba-Geigy (Switzerland)

Uses

Fadrozole hydrochloride is a very potent and selective inhibitory effect of the aromatase enzyme system.

Uses

Antineoplastic.

Definition

ChEBI: Fadrozole hydrochloride is an imidazopyridine.

Manufacturing Process

5-p-Cyanophenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine hydrochloride:
A solution of 2.0 g of 4-(4-chloro-4-p-cyanophenyl-n-butyl)-1H-imidazole in 50 ml of chloroform is refluxed for 4 hours under nitrogen, cooled and evaporated to yield the 5-p-cyanophenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine hydrochloride; melting point 231-233°C (from 2-propanol).
Preparation of the starting materials:
A solution of 1.82 g of 4-(3-ethoxycarbonylpropyl)-1H-imidazole in 30 ml of tetrahydrofuran under nitrogen is treated with 0.5 g of sodium hydride (50% oil dispersion) at 0°C for 30 min and 1.45 ml of trimethylsilyl chloride at 0°C for 3 hours. The reaction mixture is washed with cold 0.5 N sodium bicarbonate solution, dried over sodium sulfate and evaporated to dryness. The oil is redissolved in 100 ml of methylene chloride at -78°C under nitrogen and 12.82 ml of diisobutylaluminum hydride (1.56 M) is added dropwise. The reaction mixture is stirred for 5 min at -78°C, quenched with 1 ml of methanol followed by 10 ml of water and filtered through Celite?. The organic phase is separated, dried over sodium sulfate and evaporated to yield the title compound (a).
(b) 4-(4-p-t-Butylaminocarbonylphenyl-4-hydroxy-n-butyl)-1-trimethylsilylim idazole:6.95 g of p-tert-butylaminocarbonylbromobenzene is dissolved in 175 ml of tetrahydrofuran at -70°C under nitrogen and 20.1 ml of a solution of n-butyl lithium (2.7 m) in hexane is added dropwise. After reacting 30 min, a solution of 5.69 g of 4-(3-formyl-n-propyl)-1-trimethylsilyl imidazole in 10 ml of tetrahydrofuran is added slowly. The reaction mixture is allowed to warm slowly to room temperature and 20 ml of ammonium chloride is added. The organic layer is separated, dried over sodium sulfate and evaporated to yield the title compound (b).
(c) 4-(4-Chloro-4-p-cyanophenyl-n-butyl)-1H-imidazole:
A solution of 4.5 g of 4-(4-p-t-butylaminocarbonylphenyl-4-hydroxy-n-butyl)- 1-trimethylsilylimidazole in 50 ml of thionyl chloride is refluxed for 1 hour, cooled and evaporated. The residue is partitioned between methylene chloride and aqueous sodium bicarbonate solution. The organic phase is separated, dried over sodium sulfate and evaporated to yield the title compound (c).
5-p-Cyanophenyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine:
A solution of 2.0 g of 4-(4-chloro-4-p-cyanophenyl-n-butyl)-1H-imidazole in 50 ml of chloroform is refluxed for 4 hours under nitrogen, cooled and evaporated to yield the 5-p-cyanophenyl-5,6,7,8-tetrahydroimidazo[1,5- a]pyridine.

brand name

Afema

Therapeutic Function

Antineoplastic

Biochem/physiol Actions

Fadrozole is a nonsteroidal aromatase inhibitor. Fadrozole is a very potent and highly selective inhibitor of the aromatase enzyme system in vitro and estrogen biosynthesis in vivo. It inhibited the conversion of [4-14C]androstenedione to [4-14C]estrone by human placental microsomes in a competitive manner (Ki = 1.6 nM). At a substrate concentration 3-fold the Km, Fadrozole was 180 times more potent, as an inhibitor, than aminoglutethimide (Cat. No. A9657), exhibiting half-maximal inhibition at 1.7 nM as compared to 0.3 μM. In vivo, Fadrozole lowered ovarian estrogen synthesis by gonadotropin-primed, androstenedione treated, immature rats by 90% at a dose of 260 μg/kg (PO). In vivo, Fadrozole leads to sequelae of estrogen deprivation (e.g. regression of DMBA-induced mammary tumors) without causing adrenal hypertrophy in adult rats. It blocked aromatase by 50% in human breast cancer homogenates, live breast cancer cells, human placental microsomes, and porcine ovarian microsomes at concentrations of 0.008 to 0.02 μM.